Iovance Biotherapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 557
- Market Cap
- $3.4B
- Website
- http://www.iovance.com
- Introduction
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
- Conditions
- Cervical Carcinoma
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 189
- Registration Number
- NCT03108495
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center Center For Women's Health, Phoenix, Arizona, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of California San Diego, San Diego, California, United States
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Biological: LN-145Biological: LN-145-S1
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03083873
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT02360579
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of California Los Angeles - David Geffen School of Medicine - Westwood Rheumatology, Los Angeles, California, United States